Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease
- PMID: 15494404
- DOI: 10.1074/jbc.M410210200
Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease
Abstract
Huntington's disease (HD) is caused by an expansion of exonic CAG triplet repeats in the gene encoding the huntingtin protein (Htt), however, the means by which neurodegeneration occurs remains obscure. There is evidence that mutant Htt interacts with transcription factors leading to reduced histone acetylation. We report that administration of the histone deacetylase inhibitor phenylbutyrate after onset of symptoms in a transgenic mouse model of HD significantly extends survival and attenuates both gross brain and neuronal atrophy. Administration of phenylbutyrate increased brain histone acetylation and decreased histone methylation levels as assessed by both immunocytochemistry and Western blots. Phenylbutyrate increased mRNA for components of the ubiquitin-proteosomal pathway and down-regulated caspases implicated in apoptotic cell death, and active caspase 3 immunoreactivity in the striatum. These results show that administration of phenylbutyrate, at doses that are well tolerated in man, exerts significant neuroprotective effects in a transgenic mouse model of HD, and therefore represents a very promising therapeutic approach for HD.
Similar articles
-
Selective histone deacetylase (HDAC) inhibition imparts beneficial effects in Huntington's disease mice: implications for the ubiquitin-proteasomal and autophagy systems.Hum Mol Genet. 2012 Dec 15;21(24):5280-93. doi: 10.1093/hmg/dds379. Epub 2012 Sep 10. Hum Mol Genet. 2012. PMID: 22965876 Free PMC article.
-
Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease.J Neurochem. 2013 May;125(3):410-9. doi: 10.1111/jnc.12190. Epub 2013 Mar 5. J Neurochem. 2013. PMID: 23373812 Free PMC article.
-
Altered selenium status in Huntington's disease: neuroprotection by selenite in the N171-82Q mouse model.Neurobiol Dis. 2014 Nov;71:34-42. doi: 10.1016/j.nbd.2014.06.022. Epub 2014 Jul 8. Neurobiol Dis. 2014. PMID: 25014023
-
Histone deacetylase inhibitors: a novel therapeutic approach to Huntington's disease (complex mechanism of neuronal death).Curr Alzheimer Res. 2006 Sep;3(4):403-8. doi: 10.2174/156720506778249407. Curr Alzheimer Res. 2006. PMID: 17017871 Review.
-
Epigenetics of Huntington's Disease.Adv Exp Med Biol. 2017;978:277-299. doi: 10.1007/978-3-319-53889-1_15. Adv Exp Med Biol. 2017. PMID: 28523552 Review.
Cited by
-
Targeting histone deacetylases: a novel approach in Parkinson's disease.Parkinsons Dis. 2015;2015:303294. doi: 10.1155/2015/303294. Epub 2015 Jan 28. Parkinsons Dis. 2015. PMID: 25694842 Free PMC article. Review.
-
Huntington's disease and the striatal medium spiny neuron: cell-autonomous and non-cell-autonomous mechanisms of disease.Neurotherapeutics. 2012 Apr;9(2):270-84. doi: 10.1007/s13311-012-0112-2. Neurotherapeutics. 2012. PMID: 22441874 Free PMC article. Review.
-
Disease-modifying pathways in neurodegeneration.J Neurosci. 2006 Oct 11;26(41):10349-57. doi: 10.1523/JNEUROSCI.3829-06.2006. J Neurosci. 2006. PMID: 17035516 Free PMC article. Review. No abstract available.
-
Inhibition of histone deacetylase protects the retina from ischemic injury.Invest Ophthalmol Vis Sci. 2010 Jul;51(7):3639-45. doi: 10.1167/iovs.09-4538. Epub 2010 Feb 17. Invest Ophthalmol Vis Sci. 2010. PMID: 20164449 Free PMC article.
-
RE1 silencing transcription factor is involved in regulating neuron-specific expression of alpha-internexin and neurofilament genes.J Neurochem. 2009 Jun;109(6):1610-23. doi: 10.1111/j.1471-4159.2009.06052.x. Epub 2009 Mar 23. J Neurochem. 2009. PMID: 19457133 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
